ProCE Banner Activity

An Expert Review of MASLD/MASH: Focus on Screening and Diagnosis

Clinical Thought

Are you up to date on the current recommended screening and diagnosis of metabolic dysfunction–associated steatotic liver disease (MASLD)/metabolic dysfunction–associated steatohepatitis (MASH) and the identification of risk factors, including those of fibrosis? 

Released: December 21, 2023

Share

Faculty

Arun B. Jesudian

Arun B. Jesudian, MD

Associate Professor of Clinical Medicine
Director of Liver Quality and Inpatient Liver Services
Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York

Provided by

Provided by Clinical Care Options, LLC, in partnership with the American Gastroenterological Association (AGA) and Practicing Clinicians Exchange (PCE).

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Partners

AGA

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Faculty Disclosure

Primary Author

Arun B. Jesudian, MD

Associate Professor of Clinical Medicine
Director of Liver Quality and Inpatient Liver Services
Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York

Arun Jesudian, MD: consultant/advisor/speaker: Dynavax, Salix.